MT-3995

DRUG4 trials

Sponsors

Tanabe Pharma Corporation

Conditions

Diabetic NephropathyHealthyNASH

Phase 1

Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy

CompletedNCT02205372

Tanabe Pharma CorporationDiabetic Nephropathy

Start: 2014-07-31End: 2015-08-31Updated: 2015-09-16

Drug Interaction Study of Warfarin and MT-3995

CompletedNCT02531568

Tanabe Pharma CorporationHealthy

Start: 2015-06-30End: 2015-09-30Updated: 2015-10-09

Mass Balance Study of MT-3995

CompletedNCT02900235

Tanabe Pharma CorporationHealthy

Start: 2016-08-31End: 2016-12-31Updated: 2017-01-31

Phase 2

Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)

CompletedNCT02923154

Tanabe Pharma CorporationNASH

Start: 2016-09-30End: 2019-04-30Updated: 2019-09-06

Related Papers

Drug–Drug Interactions of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone With Midazolam, Warfarin, and Digoxin: A Phase 1 Studies in Healthy Volunteers

Clinical Therapeutics2020-11-016 citations